Proteomic patterns associated with ketamine response in major depressive disorders.

ABSTRACT:

Background

Major depressive disorder (MDD) is characterized by persistent feelings of sadness and loss of interest. Ketamine has been widely used to treat MDD owing to its rapid effect in relieving depressive symptoms. Importantly, not all patients respond to ketamine treatment. Identifying sub-populations who will benefit from ketamine, as well as those who may not, prior to treatment initiation, would significantly advance precision medicine in patients with MDD.

Methods

Here, we used mass spectrometry-based plasma proteomics to analyze matched pre- and post-ketamine treatment samples from a cohort of 30 MDD patients whose treatment outcomes and demographic and clinical characteristics were considered.

Results

Ketamine responders and non-responders were identified a

SUBMITTER: Zhou N 

PROVIDER: S-EPMC11723896 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature